Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
SCLN's Cash to Debt is ranked higher than
92% of the 921 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SCLN: No Debt )
SCLN' s 10-Year Cash to Debt Range
Min: 2.83   Max: No Debt
Current: No Debt

Equity to Asset 0.85
SCLN's Equity to Asset is ranked higher than
90% of the 842 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. SCLN: 0.85 )
SCLN' s 10-Year Equity to Asset Range
Min: 0.62   Max: 0.92
Current: 0.85

0.62
0.92
Interest Coverage 541.33
SCLN's Interest Coverage is ranked higher than
72% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. SCLN: 541.33 )
SCLN' s 10-Year Interest Coverage Range
Min: 34.65   Max: 9999.99
Current: 541.33

34.65
9999.99
F-Score: 8
Z-Score: 10.79
M-Score: -2.29
WACC vs ROIC
18.68%
38.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 19.28
SCLN's Operating margin (%) is ranked higher than
90% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.37 vs. SCLN: 19.28 )
SCLN' s 10-Year Operating margin (%) Range
Min: -6000   Max: 26.31
Current: 19.28

-6000
26.31
Net-margin (%) 18.70
SCLN's Net-margin (%) is ranked higher than
92% of the 870 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. SCLN: 18.70 )
SCLN' s 10-Year Net-margin (%) Range
Min: -4933.33   Max: 24.77
Current: 18.7

-4933.33
24.77
ROE (%) 16.48
SCLN's ROE (%) is ranked higher than
90% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. SCLN: 16.48 )
SCLN' s 10-Year ROE (%) Range
Min: -184.28   Max: 30.21
Current: 16.48

-184.28
30.21
ROA (%) 14.04
SCLN's ROA (%) is ranked higher than
95% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. SCLN: 14.04 )
SCLN' s 10-Year ROA (%) Range
Min: -136.57   Max: 25.6
Current: 14.04

-136.57
25.6
ROC (Joel Greenblatt) (%) 91.55
SCLN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.08 vs. SCLN: 91.55 )
SCLN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -706.12   Max: 99.26
Current: 91.55

-706.12
99.26
Revenue Growth (3Y)(%) 3.50
SCLN's Revenue Growth (3Y)(%) is ranked higher than
68% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.30 vs. SCLN: 3.50 )
SCLN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.7   Max: 125.7
Current: 3.5

-4.7
125.7
EBITDA Growth (3Y)(%) -2.40
SCLN's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SCLN: -2.40 )
SCLN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -53.8   Max: 13.5
Current: -2.4

-53.8
13.5
EPS Growth (3Y)(%) -0.70
SCLN's EPS Growth (3Y)(%) is ranked higher than
72% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SCLN: -0.70 )
SCLN' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.7   Max: 132.1
Current: -0.7

-58.7
132.1
» SCLN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SCLN Guru Trades in Q1 2014

Jim Simons 263,007 sh (+11.96%)
Chuck Royce 15,100 sh (+10.22%)
John Burbank Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2014

SCLN Guru Trades in Q2 2014

Jim Simons 321,326 sh (+22.17%)
Chuck Royce 15,100 sh (unchged)
» More
Q3 2014

SCLN Guru Trades in Q3 2014

Paul Tudor Jones 42,053 sh (New)
Chuck Royce 5,000 sh (-66.89%)
Jim Simons 85,900 sh (-73.27%)
» More
Q4 2014

SCLN Guru Trades in Q4 2014

Jim Simons 199,420 sh (+132.15%)
Chuck Royce 5,000 sh (unchged)
Paul Tudor Jones 41,174 sh (-2.09%)
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.40
SCLN's P/E(ttm) is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.40 vs. SCLN: 18.40 )
SCLN' s 10-Year P/E(ttm) Range
Min: 6.29   Max: 189.41
Current: 18.4

6.29
189.41
Forward P/E 22.88
SCLN's Forward P/E is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 67.57 vs. SCLN: 22.88 )
N/A
PE(NRI) 18.20
SCLN's PE(NRI) is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.00 vs. SCLN: 18.20 )
SCLN' s 10-Year PE(NRI) Range
Min: 6.32   Max: 280
Current: 18.2

6.32
280
P/B 2.90
SCLN's P/B is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. SCLN: 2.90 )
SCLN' s 10-Year P/B Range
Min: 0.82   Max: 6.15
Current: 2.9

0.82
6.15
P/S 3.39
SCLN's P/S is ranked higher than
67% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.26 vs. SCLN: 3.39 )
SCLN' s 10-Year P/S Range
Min: 0.67   Max: 12.41
Current: 3.39

0.67
12.41
PFCF 17.60
SCLN's PFCF is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 639.25 vs. SCLN: 17.60 )
SCLN' s 10-Year PFCF Range
Min: 3.83   Max: 458
Current: 17.6

3.83
458
POCF 16.77
SCLN's POCF is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 37.05 vs. SCLN: 16.77 )
SCLN' s 10-Year POCF Range
Min: 3.76   Max: 458
Current: 16.77

3.76
458
EV-to-EBIT 13.48
SCLN's EV-to-EBIT is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.20 vs. SCLN: 13.48 )
SCLN' s 10-Year EV-to-EBIT Range
Min: -35   Max: 207.3
Current: 13.48

-35
207.3
Shiller P/E 24.30
SCLN's Shiller P/E is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.29 vs. SCLN: 24.30 )
SCLN' s 10-Year Shiller P/E Range
Min: 15.13   Max: 218.5
Current: 24.3

15.13
218.5
Current Ratio 5.30
SCLN's Current Ratio is ranked higher than
88% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. SCLN: 5.30 )
SCLN' s 10-Year Current Ratio Range
Min: 1.84   Max: 9.68
Current: 5.3

1.84
9.68
Quick Ratio 4.90
SCLN's Quick Ratio is ranked higher than
88% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. SCLN: 4.90 )
SCLN' s 10-Year Quick Ratio Range
Min: 1.53   Max: 9
Current: 4.9

1.53
9
Days Inventory 223.59
SCLN's Days Inventory is ranked higher than
61% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. SCLN: 223.59 )
SCLN' s 10-Year Days Inventory Range
Min: 171.31   Max: 2281.25
Current: 223.59

171.31
2281.25
Days Sales Outstanding 109.04
SCLN's Days Sales Outstanding is ranked higher than
66% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. SCLN: 109.04 )
SCLN' s 10-Year Days Sales Outstanding Range
Min: 80.45   Max: 232.02
Current: 109.04

80.45
232.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.70
SCLN's Price/Net Cash is ranked higher than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SCLN: 7.70 )
SCLN' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 343.8
Current: 7.7

2.06
343.8
Price/Net Current Asset Value 4.80
SCLN's Price/Net Current Asset Value is ranked lower than
64% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. SCLN: 4.80 )
SCLN' s 10-Year Price/Net Current Asset Value Range
Min: 0.93   Max: 21.88
Current: 4.8

0.93
21.88
Price/Tangible Book 3.60
SCLN's Price/Tangible Book is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. SCLN: 3.60 )
SCLN' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 17.88
Current: 3.6

0.84
17.88
Price/DCF (Projected) 1.20
SCLN's Price/DCF (Projected) is ranked lower than
56% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.40 vs. SCLN: 1.20 )
SCLN' s 10-Year Price/DCF (Projected) Range
Min: 0.78   Max: 3.1
Current: 1.2

0.78
3.1
Price/Median PS Value 1.40
SCLN's Price/Median PS Value is ranked lower than
60% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. SCLN: 1.40 )
SCLN' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 66.67
Current: 1.4

0.26
66.67
Price/Graham Number 1.70
SCLN's Price/Graham Number is ranked lower than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. SCLN: 1.70 )
SCLN' s 10-Year Price/Graham Number Range
Min: 0.89   Max: 4.95
Current: 1.7

0.89
4.95
Earnings Yield (Greenblatt) 7.50
SCLN's Earnings Yield (Greenblatt) is ranked higher than
91% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SCLN: 7.50 )
SCLN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 482.2
Current: 7.5

0.5
482.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:SPJ.Germany,
SciClone Pharmaceuticals, Inc., a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as a vaccine adjuvant according to the local regulatory approvals. It markets approximately 10 partnered products in China, including Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. It competitors for existing and future products include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.
» More Articles for SCLN

Headlines

Articles On GuruFocus.com
Profits in Motion: SciClone Pharmaceuticals (SCLN), Omega Protein (OME), Zoe's Kitchen (ZOES) Mar 12 2015 
SciClone to Present at BIO CEO & Investor Conference on February 9, 2015 Jan 28 2015 
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance Jan 06 2015 
SciClone to Present at Jefferies Global Healthcare Conference on November 19th Nov 06 2014 
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2014 on November 10th Oct 30 2014 
Weekly CFO Sells Highlight: V, SCLN, VR, AMSG Jun 25 2012 
comment on SCLN Apr 29 2012 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-K/A) Dec 06 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
SCICLONE PHARMACEUTICALS INC Financials Mar 19 2015
SciClone to Present at Investor and Partnering Conferences in China Mar 19 2015
SciClone to Present at Investor and Partnering Conferences in China Mar 19 2015
SCICLONE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 12 2015
SciClone (SCLN) Beats on Q4 Earnings, Gives 2015 Outlook - Analyst Blog Mar 12 2015
SciClone posts 4Q profit Mar 11 2015
SciClone posts 4Q profit Mar 11 2015
SciClone Reports 2014 Financial Results and 2015 Outlook Mar 11 2015
SciClone Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Mar 11 2015
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 11 2015
SciClone Reports 2014 Financial Results and 2015 Outlook Mar 11 2015
Q4 2014 SciClone Pharmaceuticals Inc Earnings Release - After Market Close Mar 11 2015
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2014 on... Feb 25 2015
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2014 on... Feb 25 2015
Correction: SciClone to Present at BIO CEO & Investor Conference on February 9, 2015 at 11 am ET Jan 28 2015
SciClone to Present at BIO CEO & Investor Conference on February 9, 2015 Jan 28 2015
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 06 2015
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance Jan 06 2015
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance Jan 06 2015
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK